Tyra Biosciences, Inc. Common Stock TYRA
i
Market datapartial · fetched 2026-11-12T01:02:08.265Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:01.085243186Z
FundamentalsAlpha Vantage · unavailable
Tyra Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.84 | 457.9% | 40.9% | |||
| 25Δ | ||||||
| 30Δ | 52.61 | 597.1% | 162.6% | 18.45 | 240.8% | 20.9% |
| 35Δ | 35.15 | 447.3% | 79.3% | 19.46 | 234.4% | 17.9% |
| 40Δ | 28.04 | 350.0% | 45.4% | 20.25 | 219.8% | 15.1% |
| 45Δ | 24.54 | 283.2% | 28.7% | 20.78 | 195.8% | 12.6% |
| 50Δ | 22.44 | 232.9% | 18.7% | 21.31 | 171.9% | 10.1% |
| 55Δ | 21.48 | 200.6% | 14.1% | 21.83 | 147.9% | 7.6% |
| 60Δ | 20.52 | 168.3% | 9.5% | 22.36 | 124.0% | 5.0% |
| 65Δ | 19.81 | 145.7% | 6.6% | 22.79 | 112.5% | 3.9% |
| 70Δ | 19.40 | 134.4% | 5.5% | 23.18 | 105.3% | 3.2% |
| 75Δ | 18.98 | 123.0% | 4.4% | 23.58 | 98.1% | 2.6% |
| 80Δ | 18.57 | 111.6% | 3.3% | 23.97 | 91.0% | 1.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.84
- IV
- 457.9%
- B/E move
- 40.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 52.61
- IV
- 597.1%
- B/E move
- 162.6%
- Pseudo strike
- 18.45
- IV
- 240.8%
- B/E move
- 20.9%
35Δ
- Pseudo strike
- 35.15
- IV
- 447.3%
- B/E move
- 79.3%
- Pseudo strike
- 19.46
- IV
- 234.4%
- B/E move
- 17.9%
40Δ
- Pseudo strike
- 28.04
- IV
- 350.0%
- B/E move
- 45.4%
- Pseudo strike
- 20.25
- IV
- 219.8%
- B/E move
- 15.1%
45Δ
- Pseudo strike
- 24.54
- IV
- 283.2%
- B/E move
- 28.7%
- Pseudo strike
- 20.78
- IV
- 195.8%
- B/E move
- 12.6%
50Δ
- Pseudo strike
- 22.44
- IV
- 232.9%
- B/E move
- 18.7%
- Pseudo strike
- 21.31
- IV
- 171.9%
- B/E move
- 10.1%
55Δ
- Pseudo strike
- 21.48
- IV
- 200.6%
- B/E move
- 14.1%
- Pseudo strike
- 21.83
- IV
- 147.9%
- B/E move
- 7.6%
60Δ
- Pseudo strike
- 20.52
- IV
- 168.3%
- B/E move
- 9.5%
- Pseudo strike
- 22.36
- IV
- 124.0%
- B/E move
- 5.0%
65Δ
- Pseudo strike
- 19.81
- IV
- 145.7%
- B/E move
- 6.6%
- Pseudo strike
- 22.79
- IV
- 112.5%
- B/E move
- 3.9%
70Δ
- Pseudo strike
- 19.40
- IV
- 134.4%
- B/E move
- 5.5%
- Pseudo strike
- 23.18
- IV
- 105.3%
- B/E move
- 3.2%
75Δ
- Pseudo strike
- 18.98
- IV
- 123.0%
- B/E move
- 4.4%
- Pseudo strike
- 23.58
- IV
- 98.1%
- B/E move
- 2.6%
80Δ
- Pseudo strike
- 18.57
- IV
- 111.6%
- B/E move
- 3.3%
- Pseudo strike
- 23.97
- IV
- 91.0%
- B/E move
- 1.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 87.76% | |
| 89.84% | |
| 85.25% | |
| 84.60% | |
| 87.34% | |
| 94.21% | |
| 74.07% | |
| 78.42% | |
| 77.60% | |
| 89.77% |
Biotechnology
UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is…
More →URGN
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and…
More →VANI
Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery systems. The company…
More →VCEL
Description unavailable
More →VERA
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United…
More →